ZNTL

Announcements

Nothing here yet

Daily updates

• Zentalis Pharmaceuticals reported interim overall survival results from Part 1b of its DENALI study, showing median overall survival of 15.8 months with azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, versus 7.5 months in Cyclin E1-negative subjects.Oct 19, 2026

FDA designations

Nothing here yet

News

• Zentalis Pharmaceuticals announces first overall survival data for azenosertib from DENALI Part 1b in an abstract for ESMO Congress 2026Oct 19, 2026
• Zentalis Pharmaceuticals dosed the first patient in the Phase 3 ASPENOVA trial of azenosertib in ovarian cancerMay 5, 2026
• Zentalis selected 400mg QD 5:2 dosing of azenosertib as the pivotal study regimen in ovarian cancerApr 9, 2026